What is the current valuation of the India porokeratosis market in 2024?

The market valuation was $48.4 Million in 2024. Read More

What is the projected market size for the India porokeratosis market by 2035?

The projected valuation for 2035 is $154.64 Million. Read More

What is the expected CAGR for the India porokeratosis market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 11.14%. Read More

What are the main segments of the India porokeratosis market?

The main segments include type, diagnosis & treatment, and end-user. Read More

How much revenue did the Disseminated Actinic Porokeratosis (DSAP) segment generate in 2024?

The DSAP segment generated $15.0 Million in 2024. Read More

What is the revenue forecast for the treatment segment by 2035?

The treatment segment is projected to reach $116.64 Million by 2035. Read More

What is the revenue contribution of hospitals and clinics in the India porokeratosis market?

Hospitals and clinics contributed $20.0 Million in 2024. Read More

How does the revenue of diagnostic centers compare to that of drug stores in 2024?

Diagnostic centers generated $10.0 Million, while drug stores generated $8.0 Million in 2024. Read More

What is the revenue range for Punctate Porokeratosis from 2024 to 2035?

The revenue for Punctate Porokeratosis is expected to range from $8.4 Million to $31.64 Million. Read More

India Porokeratosis Market

Q: Which companies are the key players in the India porokeratosis market?

Key players include Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Pfizer Inc, Sanofi S.A., Mylan N.V., and Galderma S.A. Read More

ID: MRFR/HC/54310-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

India Porokeratosis Market Research Report By Type (DSAP, Linear Porokeratosis, Peoddn, Others) and By Diagnosis & Treatment (Biopsy, 5-Fluorouracil, Photodynamic Therapy, Retinoids, Cryotherapy, Lasers, Others) - Growth & Industry Forecast 2025 To 2035

India Porokeratosis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)11.14%

2024 Market Size$ 48.4 Million

2025 Market Size$ 53.79 Million

2035 Market Size$ 154.64 Million

Key Players

Amgen Inc

Bristol-Myers Squibb Company

Eli Lilly and Company

Novartis AG

Pfizer Inc

Sanofi S.A.

Trends

Rising Awareness and Education
Advancements in Treatment Options
Expansion of Dermatology Services

Opportunities

Government Initiatives and Support
Increasing Incidence of Porokeratosis
Technological Advancements in Dermatology

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Disseminated Actinic Porokeratosis (DSAP)
  2. 4.1.2 Linear Porokeratosis
  3. 4.1.3 Porokeratosis of Mantoux
  4. 4.1.4 Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)
  5. 4.1.5 Punctate Porokeratosis
2. 4.2 Food, Beverages & Nutrition, BY Diagnosis & Treatment (USD Million)
  1. 4.2.1 Diagnosis
  2. 4.2.2 Treatment
3. 4.3 Food, Beverages & Nutrition, BY End-User (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Diagnostic Centers
  3. 4.3.3 Drug Stores
  4. 4.3.4 Research and Academic Institutes
  5. 4.3.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi S.A. (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Mylan N.V. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Galderma S.A. (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY TYPE
3. 6.3 INDIA MARKET ANALYSIS BY DIAGNOSIS & TREATMENT
4. 6.4 INDIA MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
8. 6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
11. 6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS & TREATMENT, 2024 (% SHARE)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS & TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS & TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

Disseminated Actinic Porokeratosis (DSAP)
Linear Porokeratosis
Porokeratosis of Mantoux
Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)
Punctate Porokeratosis

Food, Beverages & Nutrition By Diagnosis & Treatment (USD Million, 2025-2035)

Diagnosis
Treatment

Food, Beverages & Nutrition By End-User (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Drug Stores
Research and Academic Institutes
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”